$180 million! Xiangxue pharmaceutical won the exclusive rights and interests of athenex new anti-tumor drugs
-
Last Update: 2019-12-18
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Guangzhou Xiangxue Pharmaceutical Co., Ltd (hereinafter referred to as "Xiangxue pharmaceutical") and athenex, an American biopharmaceutical company, signed a license agreement to cooperate on the research, development and commercialization of athenex's products under development, such as oral paclitaxel, oral irinotecan and kx2-391 ointment (indications: actinic keratosis) The total amount of cooperation will not exceed 180 million US dollars According to the agreement, Xiangxue pharmaceutical has the exclusive right to develop and commercialize the above products under research in mainland China, Hong Kong and Macao.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
